Results 181 to 190 of about 75,992 (272)

Complete Regression of bilateral Choroidal Metastases secondary to a Cutaneous Melanoma under Immunotherapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Yenny Angela, Alena Riesmeier, Ralf Gutzmer, Miltiadis Fiorentzis, Nikolaos E. Bechrakis, Carsten Framme, Ekaterina Sokolenko   +6 more
wiley   +1 more source

Analysis of interstitial lung disease in pharmacovigilance databases: Coding challenges and interpretation biases—An update

British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2147-2161, July 2026.
Aim Clinically, interstitial lung disease (ILD) is a heterogeneous group of respiratory disorders. Due to their low incidence, pharmacovigilance database analysis is useful to detect them. Precise diagnosis is challenging as well as coding in these databases. Query criteria are among the key elements for a good signal detection.
Romane Freppel, Adeline Benis, Philippe Bonniaud, Jean‐Luc Faillie, Aurélie Grandvuillemin   +4 more
wiley   +1 more source

Triple-M Overlap Syndrome Associated with Immune Checkpoint Inhibitors: A FAERS Pharmacovigilance Analysis. [PDF]

Healthcare (Basel)
Alshamsan B, Ng TL.
europepmc   +1 more source

Combination Therapy With Sintilimab and Anlotinib for Advanced Undifferentiated Pleomorphic Sarcoma: A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT This report describes the case of a 73‐year‐old woman with advanced undifferentiated pleomorphic sarcoma (UPS) who was intolerant to chemotherapy. Following amputation, she received sintilimab plus anlotinib and achieved a partial response with 76.6% tumor reduction.
Yan Chen, Ronghua Chu
wiley   +1 more source

Immune checkpoint inhibitor-associated hepatotoxicity and ileitis: a diagnostic challenge in a patient on long-term nivolumab therapy. [PDF]

Oxf Med Case Reports
Shahzad F, Shahzad M, Tariq M, Fatima M, Thada PK, Niazi MUK, Wahab A, Shahzad U.   +7 more
europepmc   +1 more source

Rapid Progressive Liver Atrophy During Immune Checkpoint Inhibitor Hepatitis: Imaging Perspectives Beyond Aminotransferase Elevation

Clinical Case Reports, Volume 14, Issue 7, July 2026.
ABSTRACT Severe immune checkpoint inhibitor–associated hepatitis may progress despite only modest aminotransferase elevations, particularly in patients with cirrhosis. Recognition of atypical presentations and integration of clinical, radiologic, and multidisciplinary assessment may improve risk stratification and guide timely management of clinically ...
Chukwuka Elendu, Adetokunbo A. Adesina, Olisa S. Okabekwa, Ebube C. Mbah, Favour K. Mbakwe   +4 more
wiley   +1 more source

Updates on intratumoral therapies in melanoma

Cancer, Volume 132, Issue 13, 1 July 2026.
Abstract Intratumoral therapies provide an opportunity for novel strategies in the management of advanced melanoma. These approaches deliver concentrated doses of therapeutic immune agents directly into individual tumor(s), achieving local tumor control and induction of systemic antitumor immune responses while minimizing the risk of immune‐related ...
Vincent T. Ma, Alyssa K. Steimle, Janmesh D. Patel, Caroline Burkey, Justin C. Moser, Asad Javed, Hibba tul Rehman, Mustafa Ege Seker, Alexander Birbrair, Orhan S. Ozkan, Mark R. Albertini, Yana G. Najjar, Rajan P. Kulkarni   +12 more
wiley   +1 more source

Impact of prior immune checkpoint inhibitor on trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory analysis of the EN-DEAVOR study. [PDF]

Jpn J Clin Oncol
Narita Y, Kawakami H, Nakanishi K, Makiyama A, Sugimoto N, Konishi H, Morita S, Minashi K, Imano M, Inamoto R, Nishina T, Kawakami T, Hagiwara M, Kodera Y, Kume H, Yamaguchi K, Hashimoto W, Muro K.   +17 more
europepmc   +1 more source

Carbon Footprint of Antibody‐Based Drugs and Biologics Using Hybrid Life Cycle Assessment

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 236-244, July 2026.
Life cycle assessment of monoclonal antibodies. Biological engineering has emerged since the 1980s as one of the most efficient technologies to develop new medicines. The monoclonal antibody platform is the most widely used, representing about 15–20% of drug sales.
Sébastien Taillemite, Martin Fenelon, Marc Scherlinger, Max Piffoux   +3 more
wiley   +1 more source

Past, present and future of nivolumab: new horizons in immuno-oncology. [PDF]

Front Oncol
Madar IH, Kammarambath SR.
europepmc   +1 more source